|Mr. Philip R. Jacoby Jr.||Interim Principal Accounting Officer||244.33k||128.83k||1953|
|Mr. Jason Keefer||Interim CEO & Pres||N/A||N/A||1972|
|Ms. Linda L. Chang||Chief Financial Officer||N/A||N/A||1966|
|Dr. Alla N. Danilkovitch Ph.D.||Chief Scientific Officer||N/A||N/A||1964|
|Mr. Richard Skow||Gen. Counsel & Corp. Sec.||N/A||N/A||N/A|
Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
Osiris Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 7. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 3; Compensation: 8.